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Background: The use of complementary and alternative medicine (CAM) is widespread among children in
Germany and other European countries. Only a few studies are available on trends in pediatric CAM use over time.
The study’s objective was to present updated results for prevalence, predictors, and costs of CAM use among
German children and a comparison with findings from a previous follow-up of the same birth cohort.
Methods: Data were collected for 3013 children on their utilization of medicinal products (during the last 4 weeks)
and consultation with CAM providers (in the preceding year) from a German birth cohort study (GINIplus, 15-year
follow-up) using a self-administered questionnaire. The reported medicinal CAMs were classified into six categories
(homeopathy, herbal drugs, nutritionals, minerals and trace elements, microorganisms, further CAM). Drug prices
were traced using pharmaceutical identification numbers (PZNs), or otherwise conservatively estimated. Finally, the
results were compared with data obtained from the 10-year follow-up of the same birth cohort study by adopting
the identical methodology.
Results: In all, 26% of the reported 2489 drugs were medicinal CAM. The 4-week prevalence for homeopathy and
herbal drug use was 7.5% and 5.6%, respectively. Some 13.9% of the children used at least one type of medicinal
CAM in the preceding 4 weeks. The 1-year prevalence for consultation with CAM providers was 10.8%. From the
drugs identified as CAM, 53.7% were homeopathic remedies, and 30.8% were herbal drugs.
Factors associated with higher medicinal CAM use were female gender, residing in Munich, and higher maternal
education.
A homeopathy user utilized on average homeopathic remedies worth EUR 15.28. The corresponding figure for herbal
drug users was EUR 16.02, and EUR 18.72 for overall medicinal CAM users.
Compared with the 10-year follow-up, the prevalence of homeopathy use was more than halved (−52%) and dropped
substantially for herbal drug use (−36%) and overall CAM use (−38%) as well.
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Conclusion: CAM use among 15-year-old children in the GINIplus cohort is popular, but decreased noticeably compared
with children from the same cohort at the age of 10 years. This is possibly mainly because German health legislation
normally covers CAM for children younger than 12 years only.
Keywords: Complementary therapies, CAM, Homeopathy, Phytotherapy, Child, Germany, Drug utilization, Socioeconomic
factors, TrendsBackground
Therapy approaches that are not part of conventional medi-
cine are often referred to as complementary and alternative
medicine (CAM), although there is no universally valid def-
inition of CAM. However, there seems to be an unbroken
high demand for such kinds of therapy approaches in the
European population and outside Europe as well. Some re-
cently published reviews give updated overviews on the
prevalence of CAM use in adults [1,2] and children [3,4].
Owing to different methodology and CAM definition, the
findings of the included studies on CAM use vary
widely with respect to the prevalence and predictors of
use. For instance, overall CAM use in children without
chronic conditions was reported to be between 1.8% and
87.6%, depending on included CAM modalities, country,
and underlying recall period [3].
When looking at specific CAM categories, many of
the reviewed studies listed homeopathy and herbal drugs
among the most popular types of CAM. Within Europe,
Germany ranks between the countries with the highest
prevalence rates for homeopathy and herbal drug use in
children. For homeopathy, prevalence rates of 27.7%
(1-year prevalence) [5] and 14.3% (4-week prevalence)
[6] were reported in German children. Other European
countries with high prevalence rates for homeopathy use
are The Netherlands with 14.6% (1-year prevalence) [7]
and the UK with 16.9% (lifetime use) [8]. With concern to
herbal drugs, a 2010 publication found 85.5% of German
children [9] using herbal drugs (lifetime use). In Turkey,
the prevalence of pediatric use of herbal drugs was 58.6%
(1-year prevalence) [10]. The evidently high popularity of
non-conventional medicine in Germany and other coun-
tries makes CAM use a relevant public health topic.
This article presents data from the recently completed
15-year follow-up of a German birth cohort study. The aim
was to extract prevalence rates and predictors for the
utilization of various CAM modalities (homeopathy use,
herbal drug use, medicinal CAM utilization in general, and
consultation with CAM providers). Furthermore, expendi-
tures on pediatric CAM use were analyzed. Finally, in order
to detect possible time trends and differences in CAM use,
the results were compared with the findings from the 10-
year follow-up of a smaller but similarly composed sample
from the same birth cohort.Methods
Study population
GINIplus (German Infant study on the Influence of Nutri-
tion Intervention plus environmental and genetic influ-
ences on allergy development) is a German birth cohort
study [11]. It started with 5991 healthy full-term newborns
(children with a birth weight <2500 g were not eligible for
inclusion), who were recruited between September 1995
and June 1998 from obstetric clinics in an urban region of
southern Germany (Munich) and a more rural region in
the western part of Germany (Wesel).
For the 15-year follow-up, 3895 participants were con-
tacted between January 2011 and September 2013. With re-
gard to the season, 27% of the questionnaires were collected
in winter (January–March), 29% in spring (April–June), 26%
in summer (July–September), and the remaining 18% in au-
tumn (October–December). Among other things, the
main questionnaire assessed the children’s gender, parental
income and education, and consultation with various alter-
native health care providers during the previous 12 months.
In addition to the main questionnaire, a self-adminis-
tered questionnaire on the consumption of drugs and
medicinal products was included based on an almost
identical questionnaire that had already been adopted
for the 10-year follow-up. The design of the question-
naire on drug utilization corresponds to the validated
questionnaire from the German KiGGS-Study that was
conducted with 17641 children [12]. Parents/legal guard-
ians were invited to report the drugs their child used dur-
ing the last 4 weeks by entering the drugs’ names into
designated spaces or attaching the empty drug packages to
the questionnaire.
The exact number of drugs used was assessed by an add-
itional question in case the limited number (five) of desig-
nated spaces would not suffice to report all drugs utilized.
Moreover, the participants were also asked to enter
the pharmaceutical identification number (PZN) of the
reported drugs. The PZN, which is printed on the drug
package, precisely identifies the drug utilized and pro-
vides further information such as the size of the package,
the dosage, the pharmaceutical manufacturer, the listed
price, etc.
To avoid ambiguity of interpretation, the authors
would like to note that we also considered preparations
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nutritional supplements), but were reported as drugs
utilized by the participating children.
Drug classification
All reported drugs were classified into several therapeutic
categories. The following medicinal CAM modalities were
defined and extracted from the entity of reported drugs:
(1) Homeopathic/anthroposophic drugs (afterwards
referred to as ‘Homeopathy’): Drugs that have been
prepared according to the production specification
of the Homeopathic Pharmacopoeia HAB [13],
including anthroposophic remedies and biochemic
remedies (Schuessler salts).
(2) Herbal drugs: Herbal extracts and their preparations,
teas. Preparations containing active pharmaceutical
ingredients of herbal origin (e.g., codeine) that are
available by prescription only were excluded.
(3) Nutritionals: Vitamins and combined food
supplements. Preparations containing vitamin D for
prophylaxis according to medical guidelines were
excluded.
(4) Minerals and trace elements: Mono-preparations of
minerals or trace elements such as calcium, magne-
sium, selenium, etc. Preparations containing iodide
and/or fluoride for prophylaxis according to medical
guidelines were excluded.
(5) Microorganisms: Non-pathogenic microorganisms
or their metabolites used to regulate the intestinal
flora or stimulate the immune system.
(6) Further medicinal CAM: Bach flower, traditional
Chinese medicine, etc.
As well as medicinal CAM use, consultation with CAM
providers was assessed during the previous 12 months
(non-medical health provider (‘Heilpraktiker’), homeopath,
osteopath, and ‘others’) for the child’s disease or disorder.
Cost accounting
Parents were asked to report expenditures for consulta-
tions with CAM providers. Prices for medicinal CAM
were traced via PZNs (official pharmacy prices from the
‘Lauer’ price list as of August 2012). For drug entries
without PZNs, conservative assumptions were made
(e.g., smallest package size, most favorable price).
Comparison of the results
The results were compared with data based on the 10-
year follow-up of the combined GINIplus and LISAplus
birth cohort studies (n = 3642) [6]. For comparison, only
data from the GINIplus subset were used, which in-
cluded 2065 children from Munich and Wesel. The dis-
tribution of the participants with regard to gender, studyarea, maternal educational background, and parental in-
come background was very similar to the composition of
the GINIplus cohort of the 15-year follow-up (n = 3013).
Furthermore, the same methodology (drug classification,
logistic regression model, etc.) was adopted for the analysis
of both follow-ups.Outcome definition and statistical analysis
Several outcomes were defined for the statistical analysis.
Those participants who reported utilization of at least
one homeopathic drug during the past 4 weeks were de-
fined as ‘homeopathy users’ and those taking at least one
herbal drug as ‘herbal drug users’, respectively. ‘Overall
CAM users’ took at least one drug from the therapeutic
categories 1–6. Finally, a ‘CAM provider user’ consulted
at least once during the past year with a non-medical
health provider (‘Heilpraktiker’), a homeopath, an osteo-
path, or another type of CAM provider.
The statistical analysis was performed with the SAS
software package (SAS Institute Inc., Cary, NC, USA,
version 9.3). Odds ratios (ORs) and their 95% confidence
intervals (CI) were obtained using a multivariate logistic
regression model. The significance level for the estimates
was set at p < 0.05. All independent variables included in
the model were checked using the F-test for significance.
Bivariate associations between the independent variables
and users’ prevalence rates were analyzed by Chi2 test
(p < 0.05).
To define educational status, the mothers’ educational
background was classified into four levels based on their
highest school degree:
Level 1: secondary school
Level 2: junior high school
Level 3: baccalaureate (= qualification for university
entrance)
Level 4: university degree
Mothers who reported no school degree at all (n = 5)
were allocated to education level 1. Entries for mothers
(n = 4) reporting another (not further specified) kind of
school degree than those listed above, were treated as
missing values for educational background.
The income status was defined using the median
equivalence income (MEI) for 2012 (€1633 net/month)
[14] where the household members were weighted ac-
cording to the new scale of the Organisation for Eco-
nomic Co-operation and Development (OECD) [15].
The income cut-offs were chosen according to the defin-
ition of poverty (60% of MEI) [16].
The GINIplus cohort obtained approval from the ethics
committee of the Bavarian Medical Council and the Medical
Council of North Rhine-Westphalia. Furthermore, written
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legal guardians and by participants.
Results
Cohort structure and prevalence of CAM use
Out of 3895 distributed questionnaires assessing drug
utilization, 3013 were completed and returned, yielding
a response rate of 77.4%. The children’s average age was
15.1 years, ranging between 14.5 years and 16.8 years.
Mothers completed 85.5% of the questionnaires, fathers
5.1%, and questionnaires completed by both parents
accounted for 2.7% (missing values = 6.7%). Compared
with the baseline survey, the parents of those children
who participated in the 15-year follow-up have higher
levels of school education and income. Table 1 shows
the cohort structure and the stratified prevalence rates
of CAM use. The 4-week prevalence (95% CI) of hom-
eopathy use was 7.5% [(6.5;8.5) n = 226], whereas 170
children [5.6% (4.8;6.5)] used herbal drugs. As defined in
the methods section, 10 prescription drugs containing
opium alkaloids (noscapine, morphine) or allergens ex-
tracted from pollen were excluded from the CAM mo-
dality ‘herbal drugs’. Looking at all CAM categories, 418
children [13.9% (12.6;15.1)] used at least one drug from
the CAM categories 1–6.
In sum, 1234 of the 3013 participating children re-
ported having used at least one drug during the 4 weeksTable 1 Characteristics of the GINIplus cohort and prevalence
Prevalence of use in %
n Homeopathy1 He
Gender
Male 1500 6.1 4.8
Female 1513 8.9 6.5
Study area
Munich 1457 9.0 5.8
Wesel 1556 6.1 5.5
Maternal education
Secondary school 380 5.0 3.2
Junior high school 1251 7.7 5.6
Baccalaureate 580 8.6 6.7
University degree 795 7.7 6.2
Household income
≤60% of MEI 529 6.8 4.7
60–100% of MEI 985 7.7 6.3
>100% of MEI 1071 7.8 5.6
Total 3013 7.5 5.6
Owing to missing values, the strata may not add up to the total number of particip
MEI = median equivalence income.
1Use within the last 4 weeks.
2Consultation with any type of CAM provider in the previous 12 months.
CAM provider = non-medical health practitioner, homeopath, osteopath, and ‘otherprior to the assessment date. The total number of drugs
utilized was 2489, of which 2444 could be allocated to a
therapeutic category. The remaining 45 drug entries did
not provide enough information to identify the thera-
peutic category and were therefore interpreted as drug
use only. The majority of utilized drugs were conventional
drugs with chemically active pharmaceutical ingredients
such as ibuprofen or paracetamol. Nevertheless, about
26% (n = 643) belonged to the non-conventional drug cat-
egories, as defined above in the section ‘drug classifica-
tion’. Of the 643 identified CAM, 642 were available
without medical prescription. The detailed distribution of
non-conventional drugs over the various CAM modalities
is shown in Figure 1. Homeopathic remedies were the
most commonly used CAM modality (14.1% of all identi-
fied drugs), followed by herbal drugs (8.1%), minerals and
trace elements (1.9%), and nutritionals (1.1%). Other me-
dicinal CAM modalities such as Bach flower remedies or
traditional Chinese medicine played only a marginal role.
The most mentioned homeopathic and herbal drugs are
displayed with their ATC codes in Table 2. Concerning
homeopathy, 141 of the 345 reported homeopathic remed-
ies were combined preparations. A further 146 were single
homeopathic drugs such as Arnica (n = 26), Belladonna
(n = 9), and Gelsemium (n = 9), which were the most
frequent single homeopathic remedies. Twelve drugs
were clearly identified as anthroposophic remedies.of use















Figure 1 Proportion of the single medicinal CAM modalities in
all reported medicinal CAM (n = 643).
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ing to Dr. Schuessler are partly used for several disease
patterns. An allocation to ATC categories is therefore
not possible.
With respect to herbal drugs, more than 70% of the
198 drugs from this category were used for the treat-
ment of coughs and colds. The mean duration of overall
CAM use was 11.1 days (median = 6). The correspond-
ing figures for homeopathy and herbal drugs were
9.7 days (median = 5) and 8.6 days (median = 5). In com-
parison with CAM, the mean duration of conventional
drug use was 11.4 days (median = 5).
About 47% of the minerals and trace elements (n = 47)
were preparations containing iron (n = 22). Medicinal
mono-preparations with iodide (n = 43), fluoride (n = 1),
and vitamin D (n = 6) were not defined as CAM, as they
are normally used for prophylaxis according to medical
guidelines.Table 2 Most frequent homeopathic and herbal drugs
Homeopathic drugs (n = 345)
ATC code Remedy n (in %)
R05XH20 Flu remedies* 31 (9.1)
R02AH20 Therapeutics for throat and pharynx* 14 (4.1)
R01BH20 Rhinologicals* 9 (2.6)
S02DH20 Otologicals* 8 (2.3)
M02AH20 Remedies for muscle and joint pains* 7 (2.0)
/ Single preparations 146 (42.3)
/ Biochemic remedies (= Schuessler salts) 58 (16.8)
ATC = anatomical therapeutical classification.
*Combined preparations.The prevalence for consultation with CAM providers
(within the previous 12 months) was lower than for me-
dicinal CAM use. Some 144 children (4.8%) visited a
non-medical health provider (‘Heilpraktiker’). Consult-
ation with a homeopath was reported for 98 children
(3.3%), with an osteopath for 102 children (3.4%), and 38
participants (1.3%) consulted with other CAM providers.
Overall, 324 children [10.8% (9.6;11.9)] visited at least
one type of CAM provider during the 12 months prior
to the assessment date.Predictors of CAM use
Table 3 summarizes the ORs for predicting factors for
CAM use.
Female gender significantly predicted homeopathy use
(OR = 1.48) and overall CAM use (OR = 1.49). Girls were
more likely to be ‘herbal drug users’ as well, but the ORs
were not significant for this CAM modality.
Compared with Munich (urban area), the participants
from Wesel (rural area) used fewer homeopathic drugs
(OR = 0.62) and were less likely to be ‘overall CAM
users’ (OR = 0.75). Children from Wesel also consulted
CAM providers less (OR = 0.57).
Higher education has a positive effect on CAM use.
With the lowest maternal education level as a reference,
children whose mother had a university degree showed
significantly higher ORs for herbal drug use (OR = 2.03),
and consultation with CAM providers (OR = 2.49), but
no significant association with educational status was
found for homeopathy use.
The equivalence income had no significant impact on
any category of medicinal CAM use. However, children
from poor households tend to consult CAM providers
less. Compared with the lowest income class (up to 60%
of MEI), children of parents with 60–100% of MEI vis-
ited more CAM providers (OR = 1.35; p = 0.15), and chil-
dren of parents from the highest income class (more
than 100% of MEI) had the highest ORs for consultation
with a CAM provider (OR = 1.45; p = 0.08).Herbal drugs (n = 198)
ATC code Remedy n (in %)
R01BP30 Systemic rhinologicals* 50 (25.3)
R05CA19 Expectorants (Myrtol® standardized) 23 (11.6)
R05CP02 Ivy leaves 22 (11.1)
A03FP30 Prokinetics* 18 (9.1)
R05CP05 Pelargonium root 18 (9.1)
G02CP01 Vitex agnus-castus 10 (5.1)
R05CA25 Expectorants (1,8-Cineol) 6 (3.0)
Table 3 Predictors of complementary and alternative medicine use
Adjusted odds ratio of utilization (and 95% confidence interval)
Homeopathy Herbal drugs All medicinal CAM CAM providers
Gender
Male Reference Reference Reference Reference
Female 1.48* (1.12–1.95) 1.36 (0.99–1.86) 1.49* (1.21–1.84) 1.19 (0.94–1.50)
Study area
Munich Reference Reference Reference Reference
Wesel 0.62* (0.46–0.84) 0.97 (0.69–1.36) 0.75 (0.59–0.94) 0.57** (0.44–0.74)
Maternal education
Secondary school Reference Reference Reference Reference
Junior high school 1.61 (0.96–2.68) 1.79 (0.96–3.36) 1.66 (1.12–2.45) 2.57* (1.50–4.39)
Baccalaureate 1.72 (0.99–3.01) 2.15 (1.10–4.21) 1.71 (1.12–2.62) 2.80* (1.59–4.92)
University degree 1.38 (0.79–2.41) 2.03 (1.03–3.98) 1.54 (1.00–2.35) 2.49* (1.42–4.36)
Household income
≤60% of MEI Reference Reference Reference Reference
60–100% of MEI 0.99 (0.65–1.51) 1.20 (0.74–1.96) 1.27 (0.92–1.77) 1.35 (0.90–2.03)
>100% of MEI 0.87 (0.56–1.37) 0.99 (0.59–1.67) 1.08 (0.76–1.53) 1.45 (0.96–2.20)
Bold numbers = significant at p < 0.05 *p < 0.01 **p < 0.0001.
MEI = median equivalence income.
Figure 2 Comparison of prevalence rates (10-year follow-up
(GINI-10) vs. 15-year follow-up (GINI-15)).
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Prices were traceable via PZNs for 300 (46.7%) of the
643 reported CAM. The prices of a further 324 CAM
were conservatively estimated. The remaining 19 drug
entries were not considered for cost analysis as informa-
tion content was too poor to estimate a price.
The mean price of a homeopathic drug was €10.14
(range: €3.70–€116.69), and the average price for herbal
drugs amounted to €13.72 (range: €1.99–€94.45). Looking
at all medicinal CAM, the mean cost of one drug was
€12.56, ranging between €1.02 and €116.69.
Within a period of 4 weeks, a ‘homeopathy user’ utilized
on average homeopathic drugs worth €15.28 (range:
€3.70–€124.54). The respective figures for ‘herbal drug
users’ were €16.02 (range: €1.99–€94.45) and €18.72
(range: €1.02–€181.22) for ‘overall CAM users’.
A total of 215 ‘CAM provider users’ reported expendi-
tures for consultation with a CAM provider during the
previous 12 months. The mean expenditure was €214
(range: €5–€1600).
Comparison of the results with the results from the
10-year follow-up
Children from the 15-year follow-up (= GINI-15) of the
GINIplus birth cohort used significantly less medicinal
CAM than those from the 10-year follow-up (= GINI-10).
The 4-week prevalence for homeopathy use was more
than halved, and herbal drug use dropped by more than a
third. In sum, the prevalence of overall medicinal CAMuse decreased from 22.3% (GINI-10) to 13.9% (GINI-15),
whereas the prevalence of conventional drug use increased
from 30.6% to 34.1%.
The decline in consultations with CAM providers was
lower compared with medicinal CAM use. However, the
1-year prevalence fell from 12.6% (GINI-10) to 10.8%
(GINI-15). Altogether, the prevalence of overall drug use
(conventional + non-conventional drugs put together) did
not change significantly. The prevalence rates from both
follow-ups and the mean package consumption per child
with respect to the various CAM modalities are shown in
Figures 2 and 3. Figure 4 visualizes the relative change in
CAM utilized, comparing GINI-10 with GINI-15. The
findings for predicting factors were in line with the results
from the 10-year follow-up.
Figure 3 Average consumption of drug packages (per child in
each cohort) in GINI-10 (n = 2065) and GINI-15 (n = 3013).
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The present results imply that CAM use in Germany is
considerable among 15-year-old children and confirm
the popularity of CAM among German children found
by other studies [5,6,9,17-19]. A birth cohort study from
2007 [5] analyzing homeopathy use and consultation
with a non-medical health practitioner (‘Heilpraktiker’) in
2-year-old children found a 1-year prevalence for homeop-
athy use of 27.7%. Furthermore, 4.5% of the parents had
consulted a ‘Heilpraktiker’ within the last 6 months for
their child’s disorder, which is well in line with our find-
ings for GINI-15 (4.8%, 1-year prevalence) and GINI-10
(6.2%, 1-year prevalence). Another study reporting a life-
time prevalence of 85.5% for herbal drug use [9] also in-
cluded lifetime use of herbal teas such as chamomile or
fennel, presumably explaining the very high utilization
compared with our findings.
A recent publication on herbal drug use (based on
data collected between 2003 and 2006) in a sample of
German children aged between 0 and 17 years [18]
found a 7-day prevalence of 5.8%. The same data source
yielded a 7-day prevalence for homeopathy use of 4.6%
[17]. Both results were close to the findings of the present
study for homeopathy and herbal drug use, considering
the shorter recall period (7 days vs. 4 weeks) which mayFigure 4 Relative change in pediatric CAM use (prevalence of
use and average consumption of drug packages) in GINI-15
compared with GINI-10.explain the slightly lower prevalence rates compared with
ours. Further results from studies conducted in children
with chronic conditions may have yielded higher preva-
lence rates than in the respective general population and
were therefore not considered for comparison with our
results.
The children’s financial background seems to have
only a weak impact on CAM use in Germany, but edu-
cation significantly predicted the use of several CAM
modalities. Children from the level with the lowest ma-
ternal education showed the lowest prevalence of herbal
drug use, overall CAM use, and consultation with CAM
providers, whereas there was hardly any difference be-
tween the three higher education levels. It may be as-
sumed that CAM use is also a matter of health literacy,
and children or their mothers from the lowest education
stratum are less able or less motivated to inform them-
selves about health issues such as alternative therapy ap-
proaches. Nevertheless, this positive association of drug
use with a higher maternal education level was also true
for ‘conventional drugs’.
Interestingly, the prevalence rates for medicinal CAM
use were substantially lower than the respective figures
from the 10-year follow-up in a similar German birth
cohort. In contrast to our results, most of the studies
reporting a significant association of CAM use with the
children’s age found higher prevalence rates in older
children [3]. Only three studies (two were German stud-
ies) found decreasing prevalence rates with older age
[17,18,20]. The fall in CAM use among 15-year-old chil-
dren (compared with the children from GINI-10) cannot
be explained by lower drug utilization in general, as the
consumption of ‘conventional drugs’ in GINI-15 did not
decrease at the same time. Another German study [21]
(using data collected between 2003 and 2006) showed
that the prevalence rate for drug utilization in general is
not lower in 15-year-old children than in 10-year-old
children (children aged between 14 and 17 years were
compared with children aged between 7 and 10 years).
Owing to German health legislation from 2004, statu-
tory health insurance covers costs for CAM only in excep-
tional cases for patients older than 12 years. Therefore, it
can reasonably be assumed that most of the medicinal
CAM utilized by the children in the present cohort was
bought over the counter without medical prescription or a
physician’s knowledge.
In contrast to the 15-year follow-up, statutory health in-
surance would normally cover most of the medicinal
CAM prescribed by a physician for the 10-year-old chil-
dren. De facto, 29.3% of homeopathy, 35.6% of herbal
drugs, and 31.3% of overall CAM were prescribed by phy-
sicians for the 10-year-old children in GINI-10 (prescrip-
tion status was assessed in GINI-10 only). A German
population-based study also found a reverse association of
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hypothesis is in line with our supposition that this correl-
ation may be due to the possibility of getting expenditure
on CAM reimbursed from statutory health insurance. Chil-
dren may use less CAM if it has to be paid for out of
pocket, regardless of their financial background. Consulta-
tions with CAM providers were not affected by the reim-
bursement cuts in the 2004 health act. This may explain
the moderate decline in CAM provider visits compared
with the substantial fall in medicinal CAM use.
Two longitudinal studies analyzing pediatric CAM use
[22,23] found increasing or almost stable prevalence rates
over time. A Norwegian publication presented a 1-year
prevalence of 8.7% for visits to CAM practitioners among
adolescents (17–19 years), an increase of 26% compared
with the same group surveyed 4 years before. Another lon-
gitudinal study conducted in the UK found only a small
variation in homeopathy use, with the same prevalence of
8.0% at the first and last follow-up (at the age of 18 months
and 103 months respectively; variable underlying recall
periods between 1 and 1.5 years), while the results from
the other follow-ups ranged between 5.4% and 6.6%. These
results obtained from studies with a longitudinal design
further support our hypothesis that the decrease in CAM
use in GINI-15 compared with GINI-10 may result from
German restrictions (for children older than 12 years)
concerning reimbursement for CAM.
This study has strengths and limitations as well. The
various CAM modalities were strictly classified and care-
fully extracted by a pharmacist. Owing to the almost even
distribution of data collection over winter, spring, summer,
and autumn, the seasonal impact on drug utilization was
minimized. The comparably short recall period of 4 weeks
presumably reduced recall bias. To our knowledge, only a
very few other studies have performed a longitudinal com-
parison of CAM use over time for cohorts comparable in
size and socioeconomic variables [22,23].
Compared with the German mean, the higher education
and income levels were overrepresented in the present co-
hort, because of the disproportionate number of dropouts
from the lower socioeconomic levels since the start of the
study. Additionally, it must be considered that 15-year-old
children may begin to make their own decisions concern-
ing their (self-) medication, and CAM use may also have
been influenced by the children’s educational level, which
was not assessed in this study. Furthermore, we were un-
able to rule out non-response bias, as 49.7% of the children
recruited at the beginning of the study did not participate
in the 15-year follow-up.
With regard to children who consulted a CAM pro-
vider, it must be considered that a homeopath may be a
conventional physician who uses the term ‘homeopath’
as an additional title. However, a sensitivity analysis that
excluded a ‘homeopath’ from the definition as a ‘CAMprovider’ yielded no substantial differences with regard
to the predictors of consultation with ‘non-conventional’
health providers. The questionnaire for the 15-year follow-
up did not explicitly assess whether the reported drugs
were prescribed/recommended by a physician or bought on
the children’s/parents’ own initiative. Moreover, no infor-
mation was available on the proportion of privately insured
participants among all participating children (with regard
to reimbursement for CAM, private health insurance
companies may have fewer restrictions than statutory
health insurance companies). Therefore, we cannot de-
termine exactly how much of the decrease in CAM use
(GINI-15 vs. GINI-10) can be attributed to fewer CAM
prescriptions from physicians. Nevertheless, the pro-
portion of over-the-counter drugs (such as medicinal
CAM) among all prescribed drugs is estimated to be
17% [24]. The aforementioned figure may be somewhat
lower in the present cohort, since the figure refers to the
whole German population including children younger
than 12 years. Due to potentially different definitions of
CAM, the comparability of our results with other inter-
national findings may be limited with regard to the predic-
tors and the prevalence of overall CAM use.
Prices for over-the-counter drugs are freely calculable
in Germany. The present analysis of expenditures on
CAM is based on rough price estimations. Owing to
competition, pharmacies may offer CAM at prices lower
than those listed in the official price list ‘Lauer’. On the
other hand, prices for drugs without available PZNs may
have been underestimated by conservative assumptions.
Nevertheless, we found no other German studies on
pediatric CAM use tracking or estimating prices for the
reported remedies utilized.
Conclusions
Health insurance contributions are mainly generated by
the insured persons. Therefore, it may be appropriate
that the use of these financial resources should also ad-
equately reflect the obviously existing wish of a notice-
able percentage of the German population to integrate
CAM into the treatment of their disorders. People with
minor ailments may (subjectively) experience a benefit
from the use of harmless CAM. At the same time, pa-
tients with severe conditions should be aware that CAM
is not a suitable substitute for conventional medicine.
The 2004 German health act removed nearly all over-
the-counter drugs from the list of reimbursable drugs for
children older than 12 years. This may have contributed
to the decrease in medicinal CAM use in children from
the GINI-15 cohort compared with those from GINI-10,
but other reasons such as a possibly lower acceptance of
CAM among adolescents (compared with younger chil-
dren) may have contributed to the drop in CAM use as
well. Since 2012 [25], German statutory health insurance
Italia et al. BMC Complementary and Alternative Medicine  (2015) 15:49 Page 9 of 10companies have again had the possibility to reimburse the
costs of over-the-counter drugs (including medicinal
CAM such as homeopathy, herbal drugs, etc.). Neverthe-
less, still many health insurance companies do not cover
expenditures on CAM or limit the coverage to a fixed
yearly amount [26]. For health insurers, it might be valu-
able information if reimbursement of CAM influences the
decision of insured persons to choose a specific health in-
surance company.
Future studies assessing exactly how many medicinal
CAM are prescribed by physicians may support policy
makers and health care managers in their further decision-
making process concerning the inclusion of CAM in the list
of reimbursable therapy approaches.
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